MYMETICS Corporation Announces Success of Its Preventive Vaccine Against HIV/AIDS and Commencement of European Phase 1 Human Clinical Trials

NYON, Switzerland, Feb. 9, 2009 (GLOBE NEWSWIRE) -- Mymetics (www.mymetics.com) Corporation (OTCBB:MYMX), announced today that on February 11, in Montreal, at the 16th world Conference on Retroviruses and Opportunistic Infections (CROI), Dr. Sylvain Fleury, Chief Scientific Officer of Mymetics, will present the results of a second series of preclinical trials that confirm the success of its preventive vaccine against HIV/AIDS. To date, these results are the most promising and advanced in the world. Further, they confirm a decisive path towards the prevention of transmitting HIV/AIDS. These results are of such significance that the European authorities have authorised a phase 1 clinical trial on humans.